Abstract
Background Drug-drug interactions (DDIs) are one of the main causes of adverse reactions related to medications, being responsible for up to 23% of hospital admissions. However, only a few studies have evaluated this problem in elderly Brazilians.
Objectives To determine the prevalence of potential DDIs (PDDIs) in community-dwelling elderly people in Brazil, analyse these interactions with regard to severity and clinical implications, and identify associated factors.
Methods A population-based cross-sectional study was carried out involving 2143 elderly (aged ≥60 years) residents of the metropolitan area of Sao Paulo, Brazil. Data were obtained from the SABE (Saúde, Bem estar e Envelhecimento [Health, Well-Being, and Aging]) survey, which is a multicentre study carried out in seven countries of Latin America and the Caribbean, coordinated by the Pan-American Health Organization. PDDIs were analysed using a computerized program and categorized according to level of severity, onset, mechanism and documentation in the literature. The STATA software statistical package was used for data analysis, and logistic regression was conducted to determine whether variables were associated with PDDIs.
Results Analysis revealed that 568 (26.5%) of the elderly population included in the study were taking medications that could lead to a DDI. Almost two-thirds (64.4%) of the elderly population exposed to PDDIs were women, 50.7% were aged ≥75 years, 71.7% reported having fair or poor health and 65.8% took 2–5 medications. A total of 125 different PDDIs were identified; the treatment combination of an ACE inhibitor with a thiazide or loop diuretic (associated with hypotension) was the most frequent cause of PDDIs (n=322 patients; 56.7% of individuals with PDDIs). Analysis of the PDDIs revealed that 70.4% were of moderate severity, 64.8% were supported by good quality evidence and 56.8% were considered of delayed onset. The multivariate analysis showed that the risk of a PDDI was significantly increased among elderly individuals using six or more medications (odds ratio [OR] 3.37) and in patients with hypertension (OR 2.56), diabetes mellitus (OR 1.73) or heart problems (OR 3.36).
Conclusions Approximately one-quarter of the elderly population living in Sao Paulo could be taking two or more potentially interacting medicines. Polypharmacy predisposes elderly individuals to PDDIs. More than half of these drug combinations (57.6%, n=72) were part of commonly employed treatment regimens and may be responsible for adverse reactions that compromise the safety of elderly individuals, especially at home. Educational initiatives are needed to avoid unnecessary risks.
Similar content being viewed by others
References
Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993; 27: 832–9
Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. JAMA 1997; 277: 301–6
Hohl CM, Dankoff J, Colacone A, et al. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 2001; 38: 666–71
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 200–5
Tato DS. Drug interactions facts. Saint Louis (MO): Facts and Comparisons, 2002
Bachmann KA. Drug interactions handbook. Hudson (OH): Lexi, 2003
Grahame-Smith DG, Aronson JK. Drug interactions. In: Grahame-Smith DG, Aronson JK. Oxford textbook of clinical pharmacology and drug therapy. Oxford: Oxford University Press, 2002: 105–18
Secoli SR. Drug interactions: fundamental aspects for clinical practice nursing. Rev Esc Enferm USP 2001; 35: 28–34
Fonseca RB, Secoli SR. Drugs used in bone marrow transplantation: a study about combinations of antimicrobial potentially interactives. Rev Esc Enferm USP 2008; 42: 706–14
Spitzer WO. Drug as determinants of health and disease in the population: an orientation to the bridge of pharmacoepidemiology. J Clin Epidemiol 1991; 44: 823–30
Prybys KM, Melville K, Hanna J, et al. Polypharmacy in the elderly — clinical challenges in emergency practice: part 1. Overview, etiology, and drug interactions. Emerg Med Rep 2002; 23: 145–53
Bjorkman IK, Fastbom J, Schmidt IK, et al., The Pharmaceutical Care of the Elderly in Europe Research (PEER) Group. Drug-drug interactions in the elderly. Ann Pharmacother 2002; 36: 1675–81
Passarelli MC, Jacob-Filho W, Figueras A. Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging 2005; 22: 767–77
Egger SS, Jurgen D, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 2004; 58: 773–8
Schneider JK, Mion LC, Frengley JD. Adverse drug reactions in an elderly outpatient population. Am J Hosp Pharm 1992; 49: 90–6
McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002; 36: 1331–6
Langdorf M, Fox J, Marwah R, et al. Physician versus computer knowledge of potential drug interactions in the emergency department. Acad Emerg Med 2000; 7: 1321–9
Gaddi G, Holt T, Woods M. Drug interactions in at risk emergency department patients. Acad Emerg Med 2002; 9: 1162–7
Doucet J, Chassagne P, Trivalle C, et al. Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatric Soc 1996; 44: 944–8
Bootman JL, Harrison DL, Cox E. The health care cost of drug-related morbidity and mortality in nursing facilities. Arch Intern Med 1997; 157: 2089–96
Lebrão ML, Laurenti R. Health, well-being and aging: the SABE study in São Paulo, Brazil. Rev Bras Epidemiol 2005; 8: 127–41
World Health Organization. Anatomical therapeutic chemical (ATC) classification index with defined daily doses (DDDs); Geneva, 2007 (updated on 2006 Dec 16) [online]. Available from URL: http://www.whocc.no/atcddd/index [Accessed 2007 Mar 16]
Micromedex® Healthcare Series. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc., 2007 [online]. Available from URL: http://www.thomsonhc.com [Accessed 2005 Sep 5]
Costa AJ. Potential drug interactions in an ambulatory geriatric population. Fam Pract 1991; 8: 234–6
Bergendal L, Friberg A, Schaffrath AM. Potential drug-drug interactions in 5,125 mostly elderly out-patients in Gothenburg, Sweden. Pharm World Sci 1995; 17: 152–7
Gaeta TJ, Fiorini M, Ender K, et al. Potential drug-drug interactions in elderly patients presenting with syncope. J Emerg Med 2002; 22: 159–62
Aparasu R, Baer R, Aparasu A. Clinically important potential drug-drug interactions in outpatient settings. Res Soc Administrat Pharm 2007; 3: 426–37
Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol 2003; 48: 133–43
Karas Jr S. The potential for drug interactions. Ann Emerg Med 1981; 10: 627–30
Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 1995; 155: 1949–56
Thomas A, Routledge PA. Drug interaction in clinical practice. Focus Pharmacovigilance Bull 2003: 1–7
Seymour RM, Routledge PA. Important drug-drug interactions the elderly. Drugs Aging 1998; 12: 485–94
Anderson JR, Nawarskas JJ. Cardiovascular drug-drug interactions. Cardiol Clin 2001; 19: 215–34
Ament PW, Bertolino JG, Liszewski JL. Clinically significant drug interactions. Am Fam Physician 2000; 61: 1745–54
Oscanoa T. Interaction medicamentosa em geriatría. An Facultad Medic 2006; 2: 119–26
Romero R, Castellote E, Ocon J, et al. Controlled multi-center study with quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension. J Cardiovasc Pharmacol 1995; 26: 114–8
Mahe I, Meune C, Diemer M, et al. Interaction between aspirin and ACE inhibitors in patients with heart failure. Drug Saf 2001; 24: 167–82
Malone DC, Hutchins DS, Haupert H, et al. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm 2005; 62: 1983–91
Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095–106
Chung L, Chakravarty EF, Kearns P, et al. Bleeding complications in patients on celecoxib and warfarin. J Clin Pharm Ther 2005; 30: 471–7
Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289: 1652–8
Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007; 370: 185–91
Acknowledgements
This study was supported by the Fundação de Amparo à Pesquisa do Estado de Sao Paulo (FAPESP; Sao Paulo, Brazil). FAPESP provided a research scholarship for Silvia-Regina Secoli. The Conselho Nacional de Pesquisas (CNPq; Brasilia, Brazil) provided a research productivity grant to Jair Licio Ferreira Santos. The authors have no conflicts of interest that are directly relevant to the content of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Secoli, SR., Figueras, A., Lebrão, M.L. et al. Risk of Potential Drug-Drug Interactions among Brazilian Elderly. Drugs Aging 27, 759–770 (2010). https://doi.org/10.2165/11538460-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11538460-000000000-00000